Clinical trial
A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)
NCT06590324 is registered in ClinicalTrials.gov with Resverlogix Corp as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)
- Lead sponsor
- Resverlogix Corp
- Phase
- Phase 2/3
- Overall status
- Recruiting
- Start date
- April 15, 2025
- Completion date
- March 30, 2026
- Enrollment
- 200 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.